Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

535.60INR
19 Oct 2017
Change (% chg)

Rs-4.75 (-0.88%)
Prev Close
Rs540.35
Open
Rs541.00
Day's High
Rs543.65
Day's Low
Rs532.00
Volume
62,070
Avg. Vol
477,395
52-wk High
Rs759.00
52-wk Low
Rs433.15

Chart for

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs1,272,113.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.66

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

Sensex rises ahead of key corporate results

Indian shares extended gains on Thursday with the NSE index clocking its biggest percentage gain since May 25 as excitement builds up ahead of some key quarterly results including that from Tata Consultancy Services.

12 Oct 2017

BRIEF-Sun Pharmaceutical Industries says unit raises shareholding in Ranbaxy Malaysia Sdn Bhd

* Unit agreed to increase shareholding in Ranbaxy Malaysia Sdn Bhd via purchase of 666,985 shares of Ranbaxy Malaysia Source text - http://bit.ly/2g5YoTO Further company coverage:

12 Oct 2017

Indian shares inch up; Sun Pharma rises

* Sun Pharma among top gainers after FDA ends inspection at plant

12 Oct 2017

BUZZ-India's Sun Pharma leads NSE gains; U.S. FDA issues EIR for co's Dadra plant

** Shares of Sun Pharmaceutical Industries Ltd rise as much as 3.6 pct in early trade to be top percentage gainer on NSE index

12 Oct 2017

BRIEF-Sun Pharma Industries says U.S. FDA inspection closed at co's Dadra facility‍​

* Says U.S. FDA inspection at co's Dadra facility‍​ is closed Source text - http://bit.ly/2y97tpz Further company coverage:

11 Oct 2017

BRIEF-Sun Pharmaceutical Industries gets shareholders' nod for re-appointing Dilip Shangvhi as MD

* Gets shareholders' nod for re-appointment of Dilip Shangvhi as MD Source text: http://bit.ly/2hsHpyV Further company coverage:

26 Sep 2017

BRIEF-Sun Pharmaceutical Industries says unit gets U.S. FDA nod for new label for odomzo (sonidegib)

* Says one of co's units received approval from U.S. FDA for new label for odomzo (sonidegib) Source text - http://bit.ly/2f8WIsa Further company coverage:

20 Sep 2017

MEDIA-India's Sun Pharma expects FY18 revenues to decline - PTI in Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

04 Sep 2017

BRIEF-Sun Pharmaceutical Industries seeks shareholders' nod for re-appointment of Dilip S. Shanghvi as MD

* Seeks shareholders' nod for re-appointment of dilip s. Shanghvi as managing director

31 Aug 2017

RPT-ICRA ratings for Indian debt instruments-Aug 30

(Repeating to add more ratings) Aug 30 Below are the ratings awarded by Investment Information Credit Rating Agency Ltd. (ICRA) for local debt instruments as of August 29, 2017. COMPANY INSTRUMENT RATING AMOUNT MOVEMENT (RS.MLN) ------ ---------- ------ ----- --------- SHORT TERM RATINGS: ---------------

31 Aug 2017

Earnings vs. Estimates